Puma Biotechnology Presents P-II (SUMMIT) Basket Trial Results of Neratinib for EGFR Exon 18-Mutant NSCLC at EORTC/NCI/AACR 2022
- The P-II (SUMMIT) basket trial evaluating neratinib in 582 patients with EGFR exon 18-mutant NSCLC. 79% of patients prior treated with an EGFR-targeted TKI
- In an interim efficacy, the therapy showed ORR (35%), 30% of patients pretreated with TKIs, and 50% not pretreated with TKIs, response or SD lasting for ≥ 48wks. was observed in 7 patients (6 PR, 1 SD), 3% permanently discontinued the treatment due to diarrhea
- Neratinib was approved in the US for early-stage HER2-overexpressed/amplified breast cancer & is marketed as Nerlynx. The therapy was also approved in the US in combination with capecitabine for advanced or metastatic HER2+ breast cancer & has received EC's marketing authorization for early-stage HR+ HER2-overexpressed/amplified breast cancer
Ref: Businesswire | Image: Puma Bio
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.